• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

August 2, 2013 Blood Products Advisory Committee Meeting Announcement

Center Date Time Location
CBER August 2, 2013 August 2 from 10:00 a.m. to approximately 1:30 p.m. National Institutes of Health
Building 29
Conference Room A/B
9000 Rockville Pike
Bethesda, MD 20892

Agenda
On August 2, 2013, the Committee will meet in open session to hear updates on the research programs of the Laboratory of Molecular Virology, Division of Emerging and Transfusion Transmitted Diseases, Office of Blood Research and Review, Center for Biologics Evaluation and Research, FDA.

Meeting Materials
Materials for this meeting will be available at the 2013 Blood Products Advisory Committee meetings page.

Public Participation Information
The public is welcome to attend the meeting at the specified location where a speakerphone will be provided.  Public participation in the meeting is limited to the use of the speakerphone in the conference room.  Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee.

  • Written submissions may be made to the contact person on or before July 26, 2013
  • Oral presentations on August 2, 2013 from the public will be scheduled between approximately 12:00 p.m. and 1:00 p.m. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before July 18, 2013.  Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by July 19, 2013.

Closed Committee Deliberations:
On August 2, 2013, between approximately 1:00 p.m. and 1:30 p.m., the meeting will be closed to permit discussion where disclosure would constitute a clearly unwarranted invasion of personal privacy (5 U.S.C. 552b(c)(6)).  The committee will discuss the report of the intramural research programs and make recommendations regarding personnel staffing decisions.

Contact Information

  • Bryan Emery or Pearline Muckelvene
    1401 Rockville Pike, HFM-71, Rockville, MD 20852
    301-827-1281 or 301-827-1277
    FAX: 301-827-0294
    e-mail: Bryan.Emery@fda.hhs.gov or email: Pearline.Muckelvene@fda.hhs.gov
  • FDA Advisory Committee Information Line
    1-800-741-8138 (301-443-0572 in the Washington, DC, area). Please call the Information Line for up-to-date information on this meeting.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting.

A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. Seating for this meeting may be limited but the FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Bryan Emery or Pearline Muckelvene at least 7 days in advance of the meeting. FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2). Official FR Notice